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Summary.-Between 1967 and 1978 a Phase III cooperative study was performed in
polycythaemia vera (PCV) patients who had not been treated previously with any
specific therapy other than phlebotomy. 293 patients were included and allocated at
random for either radiophosphorus therapy (146) or busulphan treatment (147).
Additional phlebotomies were indicated in both groups, to keep the haematocrit at
4247%0. 285 patients were evaluable after the study was completed, of whom 50%O
have an 8-year follow-up.
Both groups were comparable with respect to age, clinical symptoms and haemato-
logical parameters immediately before randomization. The duration of the first
remission and the overall survival were significantly better in the busulphan group.
This difference remains significant after correction for differences between the two
groups with respect to sex-ratio and phlebotomy before the start of therapy. Busul-
phan induced a longer first remission (P<0001) and a longer overall survival
(P<0 02).
POLYCYTHAEMIA VERA (PCV) is a rela- (Gilbert, 1975; Gurney, 1970; Lawrence,
tively rare disease with an annual inci- 1955; Loeb, 1975; Mantel & Haenszel,
dence of 4-6 new cases per million popula- 1959; Modan, 1975; Osgood, 1965; Perkins
tion. The mean age ofonset is 55-60 years, et al., 1964; Silverstein & Lanier, 1971).
the peak incidence occurring in the 6th The disease is generally regarded as one
decade. The mean survival time of un- of the several myeloproliferative disorders
treated patients is only about 18 months which include chronic myelogenous leu-
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kaemia, idiopathic myelofibrosis and essen-
tial thrombocytosis (Adamson et al., 1]976;
Dameshek, 1951; Gurney, 1970; Lawrence,
1955; Modan, 1965).
The pathogenesis of the disease seems
to be an uncontrolled proliferation of
marrow cells, caused by an intrinsic defect
at the stem-cell level. Evidence for an
autonomous proliferating clone of pluri-
potent stem cells has come from studies
of female patients who are also hetero-
zygous for isoenzymes of glucose-6-phos-
phate dehydrogenase. Whereas normal
tissues show both isoenzymes, only one
type is found in erythrocytes, granulocytes
and platelets in patients with PCV
(Adamson et al., 1976).
The fact that erythroid precursor cells
in PCV proliferate in vitro in the absence
of demonstrable erythropoietin may be
taken as additional evidence of autono-
mous cell growth (Eaves & Eaves, 1978).
The 3 therapeutic measures which are
available at the present time are phle-
botomy (Halnan & Russell, 1965; Mantel
& Haenszel, 1959; Perkins et al., 1964),
irradiation with radioactive phosphorus,
32p (Harman & Ledlie, 1976; Henning
et al., 1965; Hor & Pabst, 1973; Modan,
1965; Tubiana et al., 1968) and cytostatic
agents (Clarysse et al., 1976; Urasinski &
Mysik, 1970). Earlier studies have sugges-
ted that 32p treatment and myelosup-
pressive agents may yield better results
than phlebotomy (Halnan & Russell,
1965; Harman & Ledlie, 1967; Modan &
Lilienfeld, 1.965; Perkins et al., 1964;
Tubiana et al., 1968; Urasinski & Mysik,
1970) though this was not corroborated in
a retrospective epidemiological study by
Silverstein & Lanier (1971).
In Phase II studies, it has been shown
that 32p (Harman & Ledlie, 1976; Hen-
ning et al., 1965; Hor & Pabst, 1973;
Tubiana et al., 1968) and cytostatic agents
(Clarysse et al., 1]976; Landaw, 1976;
Urasinski & Mysik, 1970) induce long-
lasting remissions and prolong survival.
However, a considerable debate has
arisen over whether transition of PCV
into acute leukaemia or myelofibrosis,
which occurs in 10-15% of patients, is a
complication inherent in the nature of
the disease, or whether it arises as a result
of the type of therapy (Landaw, 1976;
Lawrence, 1955; Lawrence et al., 1969;
Ledlie, 1960; Modan & Lelienfeld, 1965;
Modan, 1975; Silverstein & Lanier, 1971;
Tubiana et al., 1968).
In 1967 a Phase III study was started
to assess the effects of both treatments
on (1) the duration of remission, (2) the
length of survival, and (3) the frequency
and types of complications occurring in
patients with PCV, especially theincidence
oftransition to acuteleukaemia, to "spent"
polycythaemia and to myelofibrosis.
PATIENTS AND METHODS
Since 1967 293 patients, never treated
before by 32p or cytostatics, have been in-
cluded in the trial and allocated at random to
treatment: 146 to a 32p group and 147 to a
busulphan group. Eight patients out of the
293 were subsequently eliminated from the
analysis because they were lost to follow-up.
At the time of reporting 5000 of patients
have been followed up for 8 years.
Diagnosis of PCV was based on erythro-
cytosis with raised RBC mass, normal
arterial 02 saturation, splenomegaly and
signs of panmyelosis in the marrow. Patients
with secondary erythrocytosis were excluded.
Previous phlebotomy was not a reason for
exclusion.
The dose of 32p was administered i.v.
(0.5-1 0 mCi/10 kg body wt). Busulphan was
given orally in a dose of 4-6 mg/day for 4-6
wAeeks, or withheld w%hen the platelet count
dropped (< 120,000/ul). In each group the
haematocrit was maintained at 42-470 by
supplementary phlebotomies, if necessary.
When a relapse occurred the same treatment
writh either 32p or busulphan was re-adminis-
tered. All randomized patients were followed
carefully w%ith periodic physical and labora-
tory examination, and the follow-up data
were monitored for signs of toxicity, compli-
cations of the disease and haematological
parameters. The follow-up forms were sent
every 6 months to the trial secretary for
statistical analysis. The results are evaluated
according to the following criteria of assess-
ment:
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1. The first remission duration. defined as
the period elapsed from randomization to one
of the following events, whichever occurred
first: clinical relapse of PCV. acute leuk-
aemia, myelosclerosis or death.
2. The complication-free survival, defined as
the period of survival elapsed from random-
ization to the first complication, such as a
vascular accident, myelosclerosis, acute leuk-
aemia, cancer or death.
3. The total survival as the time from
randomization to death.
4. The frequency and types of complica-
tions.
RESULTS
The trial was activated in 1967 and case
accrual was completed in 1978, after which
date careful follow-up was continued.
During II years, 293 untreated PCV
patients entered the study, of which 285
are evaluable. The general status and the
haematological parameters of the 2 treat-
ment groups immediately before random-
ization are summarized in Table I. Both
groups are comparable with respect to age
and clinical symptoms. The 32P group
TABLE I. Comparison of clinical symp-
toms and haematological parameters in
the 2 groups before any treatment
Thierapeutic group
32J)
No. of patients 140
Age (years) 595 (s.I. 1
Males (0/) 59
Erythrosis (O%) 81
Vascular symptorns ( 3,) 35
Goutt () 5
AMean s.(
Erytlhrocytes ( x 106) 7-3 1
Haemoglobin (%o) 19-7 2
Red cell mass (ml/kg) 58-0 17
Polymorplhs ( x 1(3) 10-9 5
Thrombocytes
( X 103) :190 271
Palpable spleeni (0/) 70
Mlarrow biopsy:
/o with iriereasel
reticulinl 22
Busulphan
145
2.7) 60-5 (s.d. 11 5)
48
86
:14
1 (
d.
,0
1.9
.-7
AMean
7.2
19 2
59.5
10-8
438
71
20
contains alarger proportion ofmales (59 o)
than in the busulphan group (48%). It
should be noted that the proportion of
previously phlebotomized patients was
S.(d.
1.0
2 7
TABLE II. lDoses of 32P and busulphan
and the rate of use of phlebotomy in the
2 groups duringfirst remission induction
First Doses
No. (loses 32p No. busuilphan
pts (mCi) pts (mg)
7 30-45 11 <80
42 4-5-6-0 17 80-160
58 > 6 0 60 160-410
30 410-700
107 mean 5-9 118 mean310-6
XVitlh
plilebotomy
Withiout
27
80
21
97
somewhat larger in the 32p than in the
busulphan group; otherwise the 2 groups
at the time of randomization were almost
similar.
Table II shows the different initial doses
of 32p (mean 5-9 mCi) and the doses of
busulphan (mean 31 06 mg) during the
first remission induction. In each group
phlebotomy was used to maintain the
haematocrit at 42-47%. The rate of phle-
botomy was equal in both groups.
Duration offirst remission
The duration of the first remission is
shown in Fig. 1. Patients treated by busul-
phan show a median first remission dura-
tion of 4 years, while those treated by
32p have a median first remission of 2
years. The difference between the two
actuarial curves is statistically significant
(P< 0001).
years 2 3 4 5 6 7 8 9 10
Fo. 1. Dulration of the first remission
according to treatment -with 3P ( )3r
busulpharn (---).
100%
80%
18 2 .° 600
56 0
26:1 a 4o0/
0 ._c
26.3C 2t-0%
r-
-o- 0
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TABLE III.-First remission by treatment,
adjusted for sex and previous phlebotomy
Treat-
ment n
32p 140
Busulplian 145
Total 285
0
118
95
213
E
87-5
125-5
213-0
Logrank
O/E test
1.35>) , <0.001I
1-750
1-00
O observed number of relapses.
E-extent of exposure to risk of relapse.
O/E relative relapse rate.
It appeared that the first remission is
significantly longer in females (P < 0001)
and in patients who were not phlebotom-
ized before therapy (P < 0 001).
Because the 2 treatment groups were in
these respects somewhat different, a
statistical correction was made for sex and
phlebotomy, as shown in Table III. It
appears that the remission duration is
still significantly longer in the busulphan
group than in the group 32p (P < 0.001).
Complication-free survival
The percentages of complication-free
survival at various times after the start
of therapy are not statistically different
between the 2 treatment groups, as
demonstrated in Fig. 2, whch shows the
2 survival curves. The results are statis-
tically the same, even after correction for
sex differences and for previous phle-
botomy. The statistical analysis is given
in Table IV. Vascular complications were
more pronounced in the 32p group:
100 0/
0
6 60%-
E 0
40%-
0
years1 2 3 4 5 6 7 8 9 10
FIG. 2.- Complication-free survival curves
according to treatment with 32P ( ) or
busulphan (--).
TABLE IV.-Complication-free survival in
the 2 treatment groups adjusted for sex
andprevious phlebotomy
Treat-
ment
32p
Busulphan
Total
n
140
145
285
0
67
53
120
Logrank
E O/E test
57-7 1-160
62-3 0-85 .S
120-0 1-00
52/140 patients against 39/145 patients
treated by busulphan.
Malignant complications were observed
in 15/140 patients treated by 32p and in
14/145 patients treated by busulphan.
The types of malignancies are given in
Table V. The numbers are too small for
any conclusion to be drawn.
TABLE V.-Type of malignant complica-
tions in the 2 treatment groups
Acute leukaemia
Myeloid splenomegaly
Cancer
32p Busulphan
2 3
6 7
7* 4t
* 4 digestive tract, 1 larynx, 1 skin, 1 cerebral
sarcoma.
t 1 liver, 1 thyroid, 1 melanoma, 1 pyriform sinus.
Overall survival time
The 5-year survival in the busulphan
group was 86%, and in the 32p group
7400. The 10-year survivals were respec-
tively 700o and 5500. The overall survival
curves are shown in Fig. 3. They show a
significant difference (P = 0 02) in favour
100%
80%
60%
I.
0
> 40%
Un
20%
years1 2 3 4 5 6 7 8 9 10
FIG. 3. Overall survival curves according to
treatment with 32p ( ) or busulphan
(
-
78E.O.R.T.C.
TABLE VI. Overall survival in the 2 treat-
ment groups adjustedfor sex andprevious
phlebotomy
Tr eat -
mrent
:32 P
Busuiplpan
'I'otal
I1
140
145
285
()
47
28
75
1E
36-5
:38-5
75;0
O/E
1 29)
073}
1*00
Logrank
test
P = 002
'I'ABLE VII.-Causes of death in the 2
treatment gro
Acute leukaeinia
Myeloild splenomegaly
Cancer
Vascular complications
Other causes
Uniktnown causes
Aplasia of therapeutic origin
Total
tups
32P Busulplian
3
3 2
25 8
6 5
8 6
1
47 28
of buisulphan. This difference remains
statistically significant (P=0.02) even
when correction is made for differences in
sex and previouis phlebotomy between the
groups (Table VI). The differences in
death rate are caused by vascular com-
plications, as shown in Table VII. In the
32p grouip, 25/140 patients died from
vascular accidents, compared with 8/145
patients treated by busulphan.
DISCUSSION
'I'he significantly better results in dura-
tion of first remission and overall survival
time which were obtained with busulphan
treatment of PCV compared to those
obtained with 32p are in contrast to
results described in the literature (Law-
rence et al., 1969; Osgood, 1968; WVasser-
man, 1971, 1976). As indicated in Table I,
both treatment groups were comparable
with respect to age, clinical symptoms and
haematological parameters at the time
of randomization. According to the trial
protocol, patient follow-up and blood-
volume regulations were carried out by
the same physician at the same frequency
for both groups.
Because the first remission duration was
longer in females and in patients who were
6
not phlebotomized previously, a correc-
tion was made for both these factors in
the analysis of our data. As is shown in
Tables III and IV, the differences in treat-
ment results after statistical correction
remain significantly better in the busul-
phan group.
Malignant complications and spleno-
megaly, which may occur during evolution
into postpolycythaemic myeloid meta-
plasia (Silverstein, 1976), were observed
at the same frequency in both groups.
The major difference in overall survival
between the 2 groups is due to a much
higher frequency of vascular accidents in
the 32p group. 32p was given in the same
average dose as that used successfully in
the treatment of PCV in the literature
(Lawrence, 1976; Lawrence et al., 1969;
Osgood, 1968; Wasserman, 1976). Re-
treatment was restricted to 6-month
intervals and supplementary phlebotomies
were carried out as necessary before and
during additional 32p treatment. Busu-
phan therapy could be reinstituted earlier
if necessary, and gave more stable and
longer lasting remissions, with less need
for additional phlebotomies.
The disadvantages of using phlebotomy
are the lack of effect in those cases with
thrombocytosis, thedifficultyincontrolling
the RBC volume in active cases, and the
depletion of iron stores (Hutton, 1980),
whereas the risk ofbleeding and thrombo-
embolism is not reduced (Wasserman,
1976). This difference in remission control,
which is inherent to the mode of action of
32p, may explain the higher frequency of
vascular complications in the group.
Most trials have used as chemothera-
peutic agents chlorambucil, melphalan or
cyclophosphamide, which require periodic
cyclic administration. Busulphan-induced
remissions last for months or even years
without reinstitution of the drug, a result
not achieved with the other alkylating
agents. Busulphan should, however, never
be used continuously for more than 4-6
weeks in PCV, because of the increased
risk of producing persistent thrombocyto-
penia or leucopenia. In the dosage scheme
7980 E.O.R.T.C.
used in this trial, busulphan was un-
doubtedly superior to 32p and may there-
fore be regarded as the treatment ofchoice
in polycythaemia vera.
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